## First-Line Chemotherapy for Epithelial Ovarian Cancer **Key Point:** Paclitaxel + Carboplatin is the gold-standard first-line regimen for advanced epithelial ovarian cancer (EOC), including high-grade serous adenocarcinoma. ### Rationale for Paclitaxel + Carboplatin **High-Yield:** This combination is based on the landmark GOG-111 trial, which demonstrated superior overall survival and progression-free survival compared to cyclophosphamide + cisplatin in advanced EOC. - **Paclitaxel:** Microtubule-stabilizing agent; induces apoptosis in rapidly dividing cells - **Carboplatin:** Platinum agent; forms DNA adducts, causes cross-linking - **Synergy:** The combination targets both microtubule dynamics and DNA repair, with non-overlapping toxicity profiles ### Treatment Protocol 1. **Timing:** Administered after optimal cytoreductive surgery (goal: residual disease ≤1 cm) 2. **Dosing:** Paclitaxel 175 mg/m² IV over 3 hours + Carboplatin AUC 5–6 IV 3. **Cycles:** 6 cycles, every 21 days 4. **Bevacizumab:** May be added in recurrent or advanced disease for improved PFS ### Comparison with Other Regimens | Regimen | Use Case | Rationale | |---------|----------|----------| | Paclitaxel + Carboplatin | First-line, all stages | Standard of care; best OS/PFS | | Cisplatin + Doxorubicin | Older standard (historical) | Superseded; more toxicity | | BEP (Bleomycin + Etoposide + Cisplatin) | Germ cell tumors, not EOC | Wrong histology; not indicated | | 5-FU + Leucovorin | Colorectal cancer | Not standard for EOC | **Clinical Pearl:** Carboplatin dosing is calculated using the Calvert formula based on glomerular filtration rate (GFR) to minimize nephrotoxicity while ensuring adequate platinum exposure. **Warning:** Do not confuse epithelial ovarian cancer chemotherapy with germ cell tumor regimens (BEP) — histology determines drug choice.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.